X4 Pharmaceuticals secures up to $150M debt facility
X4 Pharmaceuticals (XFOR) said it entered into a senior secured term loan facility of up to $150M with K2 HealthVentures, replacing its previous loan agreement and providing the company with additional financial flexibility.
The first $80M tranche was funded at closing and used to fully repay the company’s previous loan, including $75M of principal and related fees, as well as associated closing costs.
An additional $70M may be made available at X4’s request, subject to K2HV approval and other conditions.
The new facility provides a larger total borrowing capacity, a longer interest-only period and a 48-month maturity, supporting X4’s corporate activities, including the potential commercial launch of mavorixafor in chronic neutropenia.
Recommended For You
Register for free to keep reading.
Create a free account to get unlimited breaking news and alerts when your stocks move.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.